These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12892628)

  • 1. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
    Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
    Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
    Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
    Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.
    Ivy DD; Calderbank M; Wagner BD; Dolan S; Nyquist AC; Wade M; Nickels WM; Doran AK
    Infect Control Hosp Epidemiol; 2009 Sep; 30(9):823-9. PubMed ID: 19637961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension.
    Alkukhun L; Bair ND; Dweik RA; Tonelli AR
    J Cardiovasc Pharmacol; 2014 Jan; 63(1):4-8. PubMed ID: 24084219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous catheter infections in pulmonary arterial hypertension.
    Gaine S; Gomberg-Maitland M
    Int J Clin Pract Suppl; 2008 Jul; (160):3-4. PubMed ID: 18638169
    [No Abstract]   [Full Text] [Related]  

  • 9. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
    Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ;
    Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treprostinil for the treatment of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Expert Opin Pharmacother; 2008 Jun; 9(8):1415-20. PubMed ID: 18473715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
    Shapiro S; Hill NS
    Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
    [No Abstract]   [Full Text] [Related]  

  • 15. Low incidence of catheter-related complications in patients with advanced pulmonary arterial hypertension undergoing continuous epoprostenol infusion.
    Nagai T; Kohsaka S; Anzai T; Yoshikawa T; Fukuda K; Sato T
    Chest; 2012 Jan; 141(1):272-273. PubMed ID: 22215838
    [No Abstract]   [Full Text] [Related]  

  • 16. Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure.
    Waxman AB; McElderry HT; Gomberg-Maitland M; Burke MC; Ross EL; Bersohn MM; Pangarkar SS; Tarver JH; Zwicke DL; Feldman JP; Chakinala MM; Frantz RP; Thompson GB; Torres F; Rauck RL; Clagg K; Durst L; Li P; Morris M; Southall KL; Peterson L; Bourge RC
    Chest; 2017 Dec; 152(6):1128-1134. PubMed ID: 28583617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treprostinil for pulmonary hypertension.
    Skoro-Sajer N; Lang I; Naeije R
    Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Switch From Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.
    Steringer-Mascherbauer R; Maria L; Reinhold F; Elisabeth S; Charlotte H; Dagmar E; Uwe F; Josef A
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):38-42. PubMed ID: 33079830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
    Ackerbauer KA; Tandon R
    J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.